<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763931</url>
  </required_header>
  <id_info>
    <org_study_id>J1232</org_study_id>
    <secondary_id>A-17427</secondary_id>
    <secondary_id>NA_00072292</secondary_id>
    <nct_id>NCT01763931</nct_id>
  </id_info>
  <brief_title>DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer</brief_title>
  <official_title>Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression &amp; Downstream Targets in Breast Cancer: DIG-HIF-1 Pharmacodynamic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn what effects digoxin (DIG) may have on human breast
      cancer tissue.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer cells grow in a low oxygen environment called hypoxia. The body normally
      controls the amount of oxygen in cells with what is known as Hypoxia-inducible factor
      (HIF)-1. HIF-1 helps cancer cells grow in low oxygen environments; therefore, if this
      function can be blocked, it may make it harder for breast cancer cells to grow. Digoxin is a
      drug that has been shown to block HIF-1 in lab studies. The investigators want to learn if it
      blocks HIF-1 in human breast cancer tissue. This will be done by comparing the tumor tissue
      from the original diagnostic biopsy to tissue that is taken at the time of surgery. The
      investigators will also be comparing tumor tissue of patients who are not randomized to take
      digoxin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 1, 2016</completion_date>
  <primary_completion_date type="Actual">April 1, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HIF-1α Protein Expression</measure>
    <time_frame>Baseline (biopsy prior to surgery) and at the end of 2 weeks digoxin treatment</time_frame>
    <description>To assess whether two weeks of daily oral digoxin therapy, as compared to no study drug, reduces the expression of Hypoxia-inducible factor (HIF)-1α protein, measured by immunohistochemistry (IHC), in surgically resected breast cancer tissue obtained from women undergoing lumpectomy or mastectomy for invasive breast cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events With Digoxin Treatment</measure>
    <time_frame>2 weeks</time_frame>
    <description>To assess safety and tolerability of two weeks of digoxin therapy in the pre-surgical setting graded according to Common Terminology Criteria for Adverse Events (CTCAE), version 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Digoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Digoxin administration for 2 weeks prior to surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No drug administration prior to surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin</intervention_name>
    <description>Digoxin once daily for 2 weeks prior to definitive breast surgery.</description>
    <arm_group_label>Digoxin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female sex

          -  18-70 years of age at time of consent.

          -  Histologically confirmed infiltrating carcinoma of the breast (Stage I-III)

          -  Unresected disease that meets scheduled to undergo definitive surgery; tumor size ≥
             1cm; grade 2 or 3 tumor or Ki-67 proliferation index of ≥ 10%; and, any estrogen
             receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2
             (HER2) status

          -  Patients must not have received any prior treatment of any kind to treat the current
             breast cancer.

          -  Prior use of hormone contraceptives and replacement therapy is allowed, but must have
             been discontinued at least 30 days prior to the diagnostic biopsy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky
             80%-100%)

          -  Patients must have normal organ and marrow function: absolute neutrophil count (ANC) ≥
             1,500/mm3; platelet count ≥ 100,000/mm3; bilirubin (total) less than or equal to the
             upper limit of normal; creatinine ≤ 1.5 times the upper limit of normal with
             creatinine clearance ≥ 50 mL/min using the Modified Cockcroft-Gault method; and, all
             of the following within normal limits: thyroid stimulating hormone (TSH), magnesium,
             potassium, sodium, calcium.

          -  Heart rate &gt; 60 beats/minute and &lt; 100 beats/minute (clinical exam).

          -  Not pregnant or nursing

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Current use of any investigational agents

          -  Radiological evidence of metastatic disease

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to digoxin

          -  Concomitant use of these drugs at baseline and for the duration of digoxin
             administration (if randomized to receive it): the calcium channel blockers diltiazem
             or verapamil; cardiac arrhythmic agents (such as quinidine, amiodarone); indomethacin
             (Indocin); alprazolam (Xanax); diuretics (such as furosemide, spironolactone,
             itraconazole); beta-blockers (such as atenolol, metoprolol); calcium carbonate
             antacids (e.g., Maalox, Tums, Rolaids); proton pump inhibitors; antidiarrheal
             adsorbents (kaolin and pectin); antibiotics; other P450 inducer/inhibitors. Note:
             Patients already receiving digoxin are also excluded.

          -  Presence of any of the following on electrocardiogram (ECG): atrial arrhythmias,
             including atrial fibrillation and flutter; AV block; heart rate &lt; 60 beats/minute and
             &gt; 100 beats/minute; ventricular Fibrillation; ventricular tachycardia; premature
             ventricular contractions; Wolff-Parkinson-White syndrome. Note: Any questions on
             cardiac eligibility should be reviewed by the Study Cardiologist for approval in
             advance of enrollment.

          -  History of any of the following, unless approval is given by the Protocol Chair: heart
             disease, including acute myocardial infarction; cardiac arrhythmias, including sick
             sinus syndrome; pulmonary disease with a known forced expiratory volume (FEV) of &lt;1.5
             or on oxygen; gastrointestinal disease, surgery or malabsorption that could
             potentially impact the absorption of the study drug; patients requiring the use of a
             feeding tube; inability to swallow tablets

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that will limit compliance with
             study requirements

          -  Any medical condition which in the opinion of the investigator puts the patient at
             risk of potentially serious complications while on this therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vered Stearns, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>January 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2013</study_first_posted>
  <results_first_submitted>January 22, 2020</results_first_submitted>
  <results_first_submitted_qc>January 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 31, 2020</results_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digoxin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Digoxin</title>
          <description>Digoxin administration for 2 weeks prior to surgery.
Digoxin: Digoxin once daily for 2 weeks prior to definitive breast surgery.</description>
        </group>
        <group group_id="P2">
          <title>No Drug Administration Prior to Surgery</title>
          <description>Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Digoxin</title>
          <description>Digoxin administration for 2 weeks prior to surgery.
Digoxin: Digoxin once daily for 2 weeks prior to definitive breast surgery.</description>
        </group>
        <group group_id="B2">
          <title>No Drug Administration Prior to Surgery</title>
          <description>Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="63" upper_limit="66"/>
                    <measurement group_id="B2" value="44" lower_limit="27" upper_limit="62"/>
                    <measurement group_id="B3" value="51" lower_limit="27" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race - White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race - Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race - Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HIF-1α Protein Expression</title>
        <description>To assess whether two weeks of daily oral digoxin therapy, as compared to no study drug, reduces the expression of Hypoxia-inducible factor (HIF)-1α protein, measured by immunohistochemistry (IHC), in surgically resected breast cancer tissue obtained from women undergoing lumpectomy or mastectomy for invasive breast cancer.</description>
        <time_frame>Baseline (biopsy prior to surgery) and at the end of 2 weeks digoxin treatment</time_frame>
        <population>Not enough tissue samples were collected to be analyzed and so no data was generated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Digoxin</title>
            <description>Digoxin administration for 2 weeks prior to surgery.
Digoxin: Digoxin once daily for 2 weeks prior to definitive breast surgery.</description>
          </group>
          <group group_id="O2">
            <title>No Drug Administration Prior to Surgery</title>
            <description>Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HIF-1α Protein Expression</title>
          <description>To assess whether two weeks of daily oral digoxin therapy, as compared to no study drug, reduces the expression of Hypoxia-inducible factor (HIF)-1α protein, measured by immunohistochemistry (IHC), in surgically resected breast cancer tissue obtained from women undergoing lumpectomy or mastectomy for invasive breast cancer.</description>
          <population>Not enough tissue samples were collected to be analyzed and so no data was generated for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events With Digoxin Treatment</title>
        <description>To assess safety and tolerability of two weeks of digoxin therapy in the pre-surgical setting graded according to Common Terminology Criteria for Adverse Events (CTCAE), version 4.</description>
        <time_frame>2 weeks</time_frame>
        <population>Adverse events with digoxin is not applicable to the group &quot;no drug administration prior to surgery&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Digoxin</title>
            <description>Digoxin administration for 2 weeks prior to surgery.
Digoxin: Digoxin once daily for 2 weeks prior to definitive breast surgery.</description>
          </group>
          <group group_id="O2">
            <title>No Drug Administration Prior to Surgery</title>
            <description>Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events With Digoxin Treatment</title>
          <description>To assess safety and tolerability of two weeks of digoxin therapy in the pre-surgical setting graded according to Common Terminology Criteria for Adverse Events (CTCAE), version 4.</description>
          <population>Adverse events with digoxin is not applicable to the group &quot;no drug administration prior to surgery&quot;</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Digoxin</title>
          <description>Digoxin administration for 2 weeks prior to surgery.
Digoxin: Digoxin once daily for 2 weeks prior to definitive breast surgery.</description>
        </group>
        <group group_id="E2">
          <title>No Drug Administration Prior to Surgery</title>
          <description>Group of participants who will not receive digoxin; however, tissue will be collected at time of definitive breast surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <description>Grade 1, unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Grade 1, possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Grade 2, unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hip Pain</sub_title>
                <description>Grade 1, unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Knee pain</sub_title>
                <description>Grade 1, unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neck spasms/pain</sub_title>
                <description>Grade 2, unrelated</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased urine output</sub_title>
                <description>Grade 1, possibly related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incisional pain</sub_title>
                <description>Maximum grade 2, unrelated to study drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The pre-operative setting was challenging for accrual and we did not meet our accrual goals. Therefore, the study was closed to accrual early. Only 6 out of 64 planned participants were enrolled, therefore there was not enough data to analyze.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vered Stearns, MD</name_or_title>
      <organization>SKCCC at Johns Hopkins</organization>
      <phone>410-614-1361</phone>
      <email>HopkinsBreastTrials@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

